Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
natCu-NOTA-TP-PSMA
- Development stage
- Preclinical
- Lead developer
- Université de Sherbrooke
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
natCu-NOTA-TP-PSMA is a non-radioactive small molecule conjugate developed by the University of Sherbrooke as a reference analog for the radiotheranostic agent [64Cu]Cu-NOTA-TP-PSMA. The compound is designed to target prostate cancer by binding to the prostate-specific membrane antigen (PSMA). Its structure consists of a PSMA-targeting ligand conjugated to a terpyridine-platinum (TP) moiety, which serves as a cytotoxic payload, and a NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) chelator complexed with natural (stable) copper. While its radioactive counterpart is intended for PET imaging and targeted radiotherapy, the natCu-NOTA-TP-PSMA analog is primarily utilized in preclinical research to evaluate binding affinity (demonstrating an IC50 of 30.6 nM) and to serve as a non-radioactive control for the assessment of PSMA modulation and cellular uptake.
- Other names
- natural copper-NOTA-TP-PSMAnatCu-NOTA-TP-PSMA conjugate
02
Targets
PSMA (Prostate-specific membrane antigen)DNA
Beyond the preview
Go deeper on natCu-NOTA-TP-PSMA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on natCu-NOTA-TP-PSMA.